Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 923,304 | 1,136,289 | 724,959 | 420,146 | 316,608 |
| Marketable Securities | 797,754 | 790,542 | 519,578 | 664,009 | 920,226 |
| Receivables | 48,109 | 30,739 | 33,801 | 18,760 | 3,362 |
| Inventories | 54,562 | 40,587 | 32,001 | 24,068 | 11,081 |
| TOTAL | $1,897,265 | $2,063,773 | $1,392,013 | $1,200,696 | $1,342,120 |
| Non-Current Assets | |||||
| PPE Net | 396,456 | 371,769 | 341,712 | 320,658 | 272,652 |
| Investments And Advances | 14,825 | 44,825 | 44,825 | 44,825 | 44,825 |
| Other Non-Current Assets | 233,076 | 236,044 | 235,449 | 8,623 | 16,057 |
| TOTAL | $644,357 | $652,638 | $621,986 | $374,106 | $333,534 |
| Total Assets | $2,541,622 | $2,716,411 | $2,013,999 | $1,574,802 | $1,675,654 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 39,392 | 71,215 | 22,671 | 59,708 | 21,772 |
| Accrued Expenses | 177,948 | 138,800 | 106,873 | 112,719 | 93,564 |
| TOTAL | $352,864 | $328,604 | $149,163 | $179,494 | $121,503 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | 30,000 | 30,000 | 30,000 | 30,000 |
| Deferred Revenues | 107,359 | 89,242 | 2,642 | 7,067 | 6,167 |
| Other Non-Current Liabilities | 285,492 | 286,725 | 287,372 | 4,965 | 4,335 |
| TOTAL | $581,671 | $630,612 | $317,850 | $93,343 | $76,032 |
| Total Liabilities | $934,535 | $959,216 | $467,013 | $272,837 | $197,535 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 111,490 | 111,208 | 106,537 | 106,258 | 101,030 |
| Common Shares | 1,113 | 1,110 | 1,064 | 1,011 | 1,009 |
| Retained earnings | -3,450,903 | -3,242,368 | -3,022,887 | -2,840,972 | -2,629,531 |
| Other shareholders' equity | -34,371 | -35,831 | -32,853 | -33,213 | -33,392 |
| TOTAL | $1,607,087 | $1,757,195 | $1,546,986 | $1,301,965 | $1,478,119 |
| Total Liabilities And Equity | $2,541,622 | $2,716,411 | $2,013,999 | $1,574,802 | $1,675,654 |